CHMP empfiehlt die Zulassung der TAF-basierten Single Tablet Odefsey®
Crossref DOI link: https://doi.org/10.1007/s15006-016-8332-8
Published Online: 2016-06-03
Published Print: 2016-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Red,